Immune Design Corp (IMDZ) saw its loss widen to $12.62 million, or $0.50 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $12.29 million, or $0.61 a share. Revenue during the quarter surged 193.34 percent to $5.46 million from $1.86 million in the previous year period. Gross margin for the quarter expanded 50 basis points over the previous year period to 99.32 percent.
Operating loss for the quarter was $12.74 million, compared with an operating loss of $12.64 million in the previous year period.
"During the first quarter of the year, we were pleased to complete enrollment in the first randomized studies for each of CMB305 and G100, an important milestone for Immune Design," said Carlos Paya, M.D., Ph.D., president and chief executive officer of Immune Design. "We hope that the emerging biomarker and clinical data that we intend to present starting at ASCO and continuing throughout 2017, may form the initial foundation to support commercialization of novel and safe immunotherapies for selected cancer patients."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
